Coloplast delivered 8% organic growth and EBIT increased by 8% to DKK 1,297m, corresponding to an EBIT margin of 30%, in the first quarter of the 2018/19 financial year. The company maintains its financial guidance for 2018/19.
Coloplast delivered 8% organic revenue growth in the first three months of the 2018/19 financial year, while reported growth in Danish kroner was up by 9% to DKK 4,321m. Currency developments reduced revenue by less than 1%, and revenue from acquisitions contributed 1%.
Organic growth rates by business area were 8% in Ostomy Care, 8% in Continence Care, 9% in Interventional Urology, and 11% in Wound & Skin Care.
Looking at sales by geography, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 14% increase.
Investments in further growth
Coloplast continued its incremental investments in growth of up to 2% of revenue during the first quarter. Investments were made in innovation as well as sales and marketing initiatives across multiple markets and business areas.
In addition, Coloplast is expanding its SpeediCath® portfolio with the launch of SpeediCath® Navi. SpeediCath® Navi is a hydrophilic catheter designed specifically for Emerging Markets and it will be launched during 2019 and 2020.
Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and a reported growth in DKK of 8-9%.
Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.
| CONTACTS |
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 07
| Ellen Bjurgert|
Vice President, Investor Relations
+45 49 11 33 76
|Financial highlights and key ratios (DKKm)||2018/19|
|EBIT margin (in DKK)||30%||31%|
|Profit for the period||991||940||5%|
|Sales performance by business area|
|Organic growth||Reported growth|
|Wound & Skin Care||527||473||11%||11%|
|Financial guidance ||Guidance for 2018/19||Guidance for 2018/19 (DKK)|
|Sales growth||~8% (organic)||8-9%|
|EBIT margin||30-31% (at constant exchange rates)||~31%|